Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer
{{output}}
Objective: To describe the effectiveness and safety of pembrolizumab in routine clinical practice as first-line treatment for advanced/metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% and without EGFR or ... ...
